Join to View Full Profile
2800 L street, ste 500Sacramento, CA 95816
Phone+1 916-454-6850
Dr. Kile is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Shawn Kile is a board-certified neurologist with expertise in treating cognitive disorders, and the Chair of the Neuroscience Service Line for Sutter Health. He cares for patients with dementia, traumatic brain injury, autism, encephalopathy, and other neurocognitive illnesses. Dr. Kile has authored numerous publications and presented internationally on new approaches to managing Alzheimer’s disease, dementia, neurobehavioral disorders and traumatic brain injury. He is a Principal Investigator for physician-initiated trials supported by the Sutter Institute for Medical Research (SIMR) and phase 2-3 clinical studies assessing the efficacy of new therapies for Alzheimer’s disease and adult autism.
Education & Training
University of California Davis HealthResidency, Neurology, 2004 - 2007- University of California Davis HealthFellowship, Forensic Psychiatry, 2003 - 2004
- University of California Davis HealthResidency, Psychiatry, 1999 - 2003
University of Texas Medical Branch School of MedicineClass of 1999
Certifications & Licensure
CA State Medical License 2000 - 2026
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment Start of enrollment: 2011 Jan 01
- Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease Start of enrollment: 2018 Jan 04
Publications & Presentations
PubMed
- 3 citationsFive-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease.Shawn Kile, William Au, Carol Parise, Kimberley Rose, Tammy Donnel
BMC Neuroscience. 2021-08-01 - 15 citationsA Randomized, Placebo-Controlled, Blinded, Crossover, Pilot Study of the Effects of Dextromethorphan/Quinidine for the Treatment of Neurobehavioral Symptoms in Adults ...Michael Chez, Shawn Kile, Christopher Lepage, Carol Parise, Bobbie Benabides
Journal of Autism and Developmental Disorders. 2020-05-01 - 8 citationsReduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment.Shawn Kile, William Au, Carol Parise, Jaideep Sohi, Tracy Yarbrough
American Journal of Alzheimer's Disease and Other Dementias. 2020-02-12
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
